Evelien Smits
Evelien Smits
Professor at University of Antwerp, Belgium
Geverifieerd e-mailadres voor uantwerp.be
Geciteerd door
Geciteerd door
Clinical use of dendritic cells for cancer therapy
S Anguille, EL Smits, E Lion, VF van Tendeloo, ZN Berneman
The lancet oncology 15 (7), e257-e267, 2014
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination
VF Van Tendeloo, A Van de Velde, A Van Driessche, N Cools, S Anguille, ...
Proceedings of the National Academy of Sciences 107 (31), 13824-13829, 2010
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy
ELJM Smits, P Ponsaerts, ZN Berneman, VFI Van Tendeloo
The oncologist 13 (8), 859-875, 2008
RNA-based gene transfer for adult stem cells and T cells
E Smits, P Ponsaerts, M Lenjou, G Nijs, DR Van Bockstaele, ...
Leukemia 18 (11), 1898-1902, 2004
Natural killer cell immune escape in acute myeloid leukemia
E Lion, Y Willemen, ZN Berneman, VFI Van Tendeloo, ELJ Smits
Leukemia 26 (9), 2019-2026, 2012
Dendritic cells as pharmacological tools for cancer immunotherapy
S Anguille, EL Smits, C Bryant, HH Van Acker, H Goossens, E Lion, ...
Pharmacological reviews 67 (4), 731-753, 2015
Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials
HH Van Acker, S Anguille, Y Willemen, EL Smits, VF Van Tendeloo
Pharmacology & therapeutics 158, 24-40, 2016
Immunosuppression induced by immature dendritic cells is mediated by TGF‐β/IL‐10 double‐positive CD4+ regulatory T cells
N Cools, VFI Van Tendeloo, E Smits, M Lenjou, G Nijs, ...
Journal of cellular and molecular medicine 12 (2), 690-700, 2008
NK cells: key to success of DC-based cancer vaccines?
E Lion, ELJM Smits, ZN Berneman, VFI Van Tendeloo
The oncologist 17 (10), 1256, 2012
Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties
S Anguille, ELJM Smits, N Cools, H Goossens, ZN Berneman, ...
Journal of translational medicine 7 (1), 109, 2009
Poly (I: C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs
R Ammi, J De Waele, Y Willemen, I Van Brussel, DM Schrijvers, E Lion, ...
Pharmacology & therapeutics 146, 120-131, 2015
Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities
J Tel, EL Smits, S Anguille, RN Joshi, CG Figdor, IJM de Vries
Blood, The Journal of the American Society of Hematology 120 (19), 3936-3944, 2012
Dendritic cell-based cancer gene therapy
ELJM Smits, S Anguille, N Cools, ZN Berneman, VFI Van Tendeloo
Human gene therapy 20 (10), 1106-1118, 2009
Interferon-α in acute myeloid leukemia: an old drug revisited
S Anguille, E Lion, Y Willemen, VFI Van Tendeloo, ZN Berneman, E Smits
Leukemia 25 (5), 739-748, 2011
mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients
E Van Gulck, E Vlieghe, M Vekemans, VFI Van Tendeloo, A Van De Velde, ...
Aids 26 (4), F1-F12, 2012
CD56 in the immune system: more than a marker for cytotoxicity?
HH Van Acker, A Capsomidis, EL Smits, VF Van Tendeloo
Frontiers in immunology 8, 892, 2017
Immunotherapy of acute myeloid leukemia: current approaches
ELJM Smits, ZN Berneman, VFI Van Tendeloo
Oncologist 14 (3), 240, 2009
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
S Anguille, AL Van de Velde, EL Smits, VF Van Tendeloo, G Juliusson, ...
Blood, The Journal of the American Society of Hematology 130 (15), 1713-1721, 2017
Tumoricidal activity of human dendritic cells
J Tel, S Anguille, CEJ Waterborg, EL Smits, CG Figdor, IJM de Vries
Trends in immunology 35 (1), 38-46, 2014
Interleukin-15-induced CD56+ myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential
S Anguille, E Lion, J Tel, IJM de Vries, K Coudere, PD Fromm, ...
PloS one 7 (12), 2012
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20